[Latin Name] Linum Usitatissimum L.

[Plant Source] from China

[Specifications]SDG20% 40% 60%

[Appearance] yellow brown powder

Plant Part Used:Seed

[Particle size] 80 Mesh

[Loss on drying] ≤5.0%

[Heavy Metal] ≤10PPM

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life] 24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[Net weight] 25kgs/drum

Product description:

Flaxseed extract is a kind of plant ligan most notably found in flaxseed. Secoisolariciresinol diglycoside, or SDG is existed as its main bioactive components. SDG is classified as a phytoestrogen since it is a plant-derived, nonsteroid compound that possesses estrogen-like activity. Flaxseed extract  SDG has weak estrogenic activity, when intake as food it will be trasfer to flax ligan which have same structure with estrogens.The level of SDG in flaxseed typically varies between 0.6% and 1.8%. Flaxseed extract powder SDG can reduce the blood lipid, cholesterin and triglyceride, it can also prevent for apoplexy, hyperension, blood clots, arteriosclerosis and arrhythmia. In addition, flax seed extract powder SDG is benificial for diabetes and CHD.

Main Function:

1.Flaxseed extract used to lose weight. Can burn surplus fat of Body;

2.Flaxseed extract will reduce allergic reaction, reduce asthma, improve arthritis;

3.Flaxseed extract with the function of improving female menstrual period syndrome;

4.Flaxseed extract can reduce the bad influence of hazardous chemicals produced when under pressure, control Stress, reduce depression and insomnia;

5.Flaxseed extract will improve skin fat content, moisten the skin smooth, soft and flexible, make the skin breath and sweat to normal, to mitigate various skin problems.

Jose S. Pulido, M.D., Professor of Opthalmology & Molecular Medicine, Mayo Clinic College of Medicine and Alan D. Marmorstein, Ph.D., Professor of Ophthalmology, Mayo Clinic College of Medicine discuss the importance of genetic testing in diagnosing macular degeneration. Three cases are outlined that have been referred to as Adult Onset Foveomacular Dystrophy, Macular Degeneration, and Best Disease. Genetic testing can be used to make these diagnoses and researchers are at the threshold of new and exciting treatments. Over the past few years Dr. Marmorstein’s laboratory has been involved in a study of stem cell models of Best Disease and other retinal degenerative diseases. Details can be found on the NIH web site. DNA is being collected along with skin fibroblasts from patients with Best Disease Adult Vitelliform Dystrophy Autosomal Recessive Bestrophinopathy, autosomal dominant vitreoretinal choroidopathy, and retinitis pigmentosa due to mutations in BEST1. The skin fibroblasts are being reprogrammed into induced pluripotent stem cells which can be differentiated into retinal pigment epithelial cells. This is the cell where Bestrophin, the product of the BEST1 gene is expressed and that’s where the pathogenic problem that results in these diseases occurs. Clinical trials are already underway using iPS cell derived retinal pigment epithelial cells for the treatment of age-related Macular Degeneration. It also allows the consideration of the same process to therapeutically treat Best Disease and Adult Vitelliform Macular Dystrophy, Autosomal Recessive Bestrophinopathy and models of the diseases can be generated of the diseases in the laboratory. This can help with the understanding of the processes that cause the disease and allow for the testing of potential therapeutic compounds to determine if they have an effect on these specific patients.

For more information, visit: https://www.mayoclinic.org/departments-centers/ophthalmology?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504

2001 STEVIA TESTING, WATER WASHING TO EXTRACT SOLUBLES. FIRST & SECOND PRESSING, AS-HARVESTED vs SHREDDED.